Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 문영철 | * |
dc.date.accessioned | 2019-10-02T01:59:58Z | - |
dc.date.available | 2019-10-02T01:59:58Z | - |
dc.date.issued | 2019 | * |
dc.identifier.issn | 1226-3303 | * |
dc.identifier.issn | 2005-6648 | * |
dc.identifier.other | OAK-25332 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/251466 | - |
dc.description.abstract | Background/Aims: Limited data are available regarding the efficacy of rivaroxaban for the treatment of cancer-associated venous thromboembolism (VTE). The aim of this study was to evaluate the effectiveness and safety of rivaroxaban for the treatment of VTE in active cancer patients. Methods: In this prospective, multicenter, open-label trial (NCT01989845), we enrolled patients with active cancer and objectively diagnosed lower-extremity deep vein thrombosis, pulmonary embolism (PE), or both from November 2013 to June 2016. Active cancer was defined as a histologically confirmed malignancy, which was diagnosed or treated within the previous 6 months, or as a recurrent/metastatic cancer. Patients received oral rivaroxaban 15 mg twice daily for first 3 weeks, followed by 20 mg once daily for 6 months. The primary outcome was the symptomatic recurrent VTE and the secondary outcomes included any recurrent VTE, major or clinically relevant non-major (CRNM) bleeding events, and overall mortality. All study outcomes were validated by blinded central adjudication. Results: Of 124 patients enrolled, 110 (88.7%) had solid cancer, 93 (75.0%) had metastatic disease, and no (88.7%) were receiving chemotherapy or radiotherapy. During the 6-month study period, seven patients experienced symptomatic recurrent VTE (cumulative incidence, 5.9%), and two patients experienced incidental recurrent PE (cumulative incidence of any recurrent VTE, 7.6%). Major bleeding events occurred in six patients (cumulative incidence, 5.3%) and CRNM bleeding events in 11 patients (cumulative incidence, 10.2%). Twenty-eight patients (overall mortality, 24.0%) died. Conclusions: Rivaroxaban is effective and safe for the treatment of VTE in patients with active cancer. | * |
dc.language | English | * |
dc.publisher | KOREAN ASSOC INTERNAL MEDICINE | * |
dc.subject | Neoplasms | * |
dc.subject | Recurrence | * |
dc.subject | Rivaroxaban | * |
dc.subject | Venous thromboembolism | * |
dc.subject | Therapeutics | * |
dc.title | Long-term rivaroxaban for the treatment of acute venous thromboembolism in patients with active cancer in a prospective multicenter trial | * |
dc.type | Article | * |
dc.relation.issue | 5 | * |
dc.relation.volume | 34 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.index | KCI | * |
dc.relation.startpage | 1125 | * |
dc.relation.lastpage | 1135 | * |
dc.relation.journaltitle | KOREAN JOURNAL OF INTERNAL MEDICINE | * |
dc.identifier.doi | 10.3904/kjim.2018.097 | * |
dc.identifier.wosid | WOS:000483430700021 | * |
dc.identifier.scopusid | 2-s2.0-85050118320 | * |
dc.author.google | Yhim, Ho-Young | * |
dc.author.google | Choi, Won-Il | * |
dc.author.google | Kim, Sung-Hyun | * |
dc.author.google | Nam, Seung-Hyun | * |
dc.author.google | Kim, Kyoung Ha | * |
dc.author.google | Mun, Yeung-Chul | * |
dc.author.google | Oh, Doyeun | * |
dc.author.google | Hwang, Hun-Gyu | * |
dc.author.google | Lee, Keun-Wook | * |
dc.author.google | Song, Eun-Kee | * |
dc.author.google | Kwon, Yong Shik | * |
dc.author.google | Bang, Soo-Mee | * |
dc.contributor.scopusid | 문영철(7003363716) | * |
dc.date.modifydate | 20240422115947 | * |